Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation

Table 5

One-way sensitivity results of bevacizumab.

Parameters	ICER (versus usual care)
	Predominantly	Minimally	Occult
Age
55	1,148	11,278	2,032
88	1,774	4,368	2,972
RR (bevacizumab versus ranibizumab)
Gain of >3 lines at 1 year
Base − 20%	1,604	4,700	2,308
Base + 20%	1,023	3,183	1,883
Loss of 3–6 lines at 1 year
Base − 20%	1,256	3,677	2,052
Base + 20%	1,272	3,937	2,101
Loss of >6 lines at 1 year
Base − 20%	1,263	3,579	1,982
Base + 20%	1,265	4,052	2,177
Gain of >3 lines at 2 years
Base − 20%	1,264	3,802	2,076
Base + 20%	1,264	3,802	2,076
Loss of 3–6 lines at 2 years
Base − 20%	975	2,142	1,572
Base + 20%	1,708	12,922	2,921
Loss of >6 lines at 2 years
Base − 20%	1,264	3,802	2,076
Base + 20%	1,264	3,802	2,076
Utility
>20/40
0.82	1,296	3,841	2,088
0.96	1,234	3,763	2,064
≤20/40 to >20/80
0.73	1,477	4,364	2,271
0.89	1,104	3,368	1,912
≤20/80 to >20/200
0.47	1,405	5,762	3,088
0.67	1,149	2,837	1,563
≤20/200 to >20/400
0.38	1,155	2,791	1,984
0.66	1,396	5,961	2,177
≤20/400
0.29	993	2,963	1,430
0.5	1,681	5,118	3,523
Cost ()
Bevacizumab per 1.25 mg
7.9	1,191	3,571	1,960
13.1	1,336	4,033	2,191
Intravitreal injection
31	1,102	3,287	1,818
51.6	1,426	4,317	2,334
Frequency of bevacizumab injections at 1 year
6	1,221	3,666	2,008
12	1,349	4,074	2,212
Frequency of bevacizumab injections at 2 years
4.5	1,234	3,707	2,029
12	1,383	4,181	2,266
Time horizon
2 years	3,935	8,498	7,227
10 years	1,277	3,353	2,064